Corvus Pharmaceuticals, Inc.
CRVS
$15.97
$0.161.01%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -6.69% | 75.47% | 73.47% | -99.57% | -66.55% |
| Total Depreciation and Amortization | 33.33% | 23.53% | 6.45% | -9.80% | -28.21% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | -60.94% | -155.16% | -151.52% | 452.75% | 197.11% |
| Change in Net Operating Assets | 303.27% | 317.30% | 278.93% | 227.99% | -52.90% |
| Cash from Operations | -22.36% | -29.00% | -44.95% | -35.72% | -35.98% |
| Capital Expenditure | -536.11% | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -575.15% | 72.27% | -3.78% | -1,033.90% | -312.25% |
| Cash from Investing | -575.24% | 71.63% | -4.38% | -1,040.21% | -312.53% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 542.00% | 3.90% | 234.35% | 226.80% | 350.16% |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -100.00% | -100.00% | -- |
| Cash from Financing | 360.17% | -25.70% | 80.86% | 78.17% | 528.03% |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 1,528.69% | -7.32% | 88.25% | -102.09% | -11.78% |